4WO Stock Overview
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Peijia Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.45 |
| 52 Week High | HK$0.52 |
| 52 Week Low | HK$0.33 |
| Beta | 0.52 |
| 1 Month Change | 3.18% |
| 3 Month Change | 17.01% |
| 1 Year Change | n/a |
| 3 Year Change | -66.62% |
| 5 Year Change | n/a |
| Change since IPO | -84.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4WO | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -0.5% | -0.3% |
| 1Y | n/a | -8.4% | 7.0% |
Return vs Industry: Insufficient data to determine how 4WO performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 4WO performed against the German Market.
Price Volatility
| 4WO volatility | |
|---|---|
| 4WO Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4WO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 4WO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,050 | Yi Zhang | www.peijiamedical.com |
Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; Sutra Hemi Valve, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ which is transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral balloon catheter; TaurusExplora, a pre-shaped guidewire; and TaurusNavi, an introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Fastunnel, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply.
Peijia Medical Limited Fundamentals Summary
| 4WO fundamental statistics | |
|---|---|
| Market cap | €322.05m |
| Earnings (TTM) | -€33.14m |
| Revenue (TTM) | €68.12m |
4.7x
P/S Ratio-9.7x
P/E RatioIs 4WO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4WO income statement (TTM) | |
|---|---|
| Revenue | CN¥517.46m |
| Cost of Revenue | CN¥146.18m |
| Gross Profit | CN¥371.28m |
| Other Expenses | CN¥623.02m |
| Earnings | -CN¥251.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 71.75% |
| Net Profit Margin | -48.65% |
| Debt/Equity Ratio | 11.4% |
How did 4WO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 06:37 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Peijia Medical Limited is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Bo Yu | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |